Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients With Sitosterolemia
Key result
Ezetimibe reduces sitosterol levels by ~21% vs. placebo in sitosterolemia.
- P<0.001
- n=37
Why the study?
Sitosterolemia causes elevated plasma plant sterols leading to premature atherosclerosis, and the effect of ezetimibe on reducing these sterols needed evaluation.
Does ezetimibe reduce plasma plant sterol levels in patients with sitosterolemia?
Population
37 patients with sitosterolemia
Comparison
Ezetimibe 10 mg/d vs placebo
Design
Multicenter double-blind randomized placebo-controlled study
Follow-up
8 weeks
Authors
Discussion
Loading...
Member takes
Implication
Ezetimibe lowers plant sterols in sitosterolemia; extends RCT evidence for absorption inhibition to this rare genetic disorder.
Study Design
Type
RCT (n=37)
Blinding
Double-blind
Randomization
Randomized
Multicenter
Yes
Structured PICO
Does ezetimibe reduce plasma plant sterol levels in patients with sitosterolemia?
P
Population
37 patients with sitosterolemia randomized to ezetimibe or placebo for 8 weeks.
I
Intervention
Ezetimibe 10 mg/d for 8 weeks
C
Comparator
Placebo for 8 weeks
O
Outcome
Plasma plant sterol levels (sitosterol and campesterol concentrations) at 8 weekssurrogate
Main Result
Absolute Event Rate: -21% vs 4%
p-value: p=<0.001
Ezetimibe significantly reduces plasma plant sterol concentrations in patients with sitosterolemia, providing an effective pharmacological treatment for this rare lipid disorder.
Cite This Study
Salen et al. (2004) conducted an RCT in Sitosterolemia (n=37). Ezetimibe vs. Placebo was evaluated on Sitosterol concentrations (p=<0.001). Ezetimibe 10 mg/d significantly reduced sitosterol concentrations by 21% compared with a 4% increase with placebo (P<0.001) over 8 weeks in patients with sitosterolemia.